BMXXClinical Trials•globenewswire•September 4, 2025 at 12:30 PM

BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sentiment:Positive (70)

Summary

(BMXX) Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on September 4, 2025 by globenewswire